Eton Pharmaceuticals has entered into an exclusive licensing and supply agreement with Sintetica SA to obtain U.S. marketing rights to two injectable product candidates.    With the addition of these product candidates, Eton now has three product candidates submitted with the FDA and expects to submit two additional NDAs by the third quarter of 2019. The licensed product candidates provide Eton with two high-volume, near-term product launch opportunities. The NDA for ET-202 was su...